Dandel Michael, Krabatsch Thomas, Falk Volkmar
Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular Surgery, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany.
Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular Surgery, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany.
Int J Cardiol. 2015 Nov 1;198:241-50. doi: 10.1016/j.ijcard.2015.06.103. Epub 2015 Jul 2.
Left ventricular assist devices (LVADs) are safer and provide better survival and better quality of life than biventricular assist devices (BVADs) but end-stage heart failure often involves both ventricles, even if its initial cause was left-sided heart disease. Right ventricular failure (RVF) is also a severe complication in about 25% of patients receiving an LVAD, with high perioperative morbidity (renal, hepatic or multi-organ failure) and mortality. Patients who receive an RV assist device (RVAD) only days after LVAD insertion fare much worse than those who receive an RVAD simultaneously with LVAD implantation. Temporary RVAD support in LVAD recipients with high risk for postoperative RVF can avoid permanent BVAD support. Thus, patients who definitely need a BVAD should already be identified preoperatively or at least intra-operatively. However, although the initial biochemical, hemodynamic and echocardiographic patient profiles at admission may suggest the need for a BVAD, many risk factors may be favorably modified by various strategies that may result in avoidance of RVF after LVAD implantation. This article summarizes the knowledge of risk factors for irreversible RVF after LVAD implantation and strategies to optimize RV function (preoperatively, intra-operatively and post-operatively) aimed to reduce the number of BVAD implantations. Special attention is focused on assessment of RV size, geometry and function in relation to loading conditions with the goal of predicting preoperatively the RV changes which might be induced by RV afterload reduction with the LVAD. The review also provides a theoretical and practical basis for clinicians intending to be engaged in this field.
左心室辅助装置(LVAD)比双心室辅助装置(BVAD)更安全,能带来更好的生存率和更高的生活质量,但终末期心力衰竭通常累及两个心室,即便其初始病因是左心疾病。右心室衰竭(RVF)也是约25%接受LVAD治疗患者的严重并发症,围手术期发病率(肾脏、肝脏或多器官衰竭)和死亡率都很高。在LVAD植入数天后才接受右心室辅助装置(RVAD)的患者,其预后远不如与LVAD植入同时接受RVAD的患者。对术后发生RVF风险高的LVAD受者给予临时RVAD支持,可避免永久性BVAD支持。因此,明确需要BVAD的患者应在术前或至少在术中就已确定。然而,尽管入院时患者最初的生化、血流动力学和超声心动图检查结果可能提示需要BVAD,但通过各种策略可能会有利地改善许多风险因素,从而避免LVAD植入后发生RVF。本文总结了LVAD植入后不可逆RVF的风险因素相关知识,以及旨在减少BVAD植入数量的优化右心室功能的策略(术前、术中和术后)。特别关注与负荷情况相关的右心室大小、形态和功能评估,目的是术前预测LVAD降低右心室后负荷可能引起的右心室变化。本综述还为有意从事该领域的临床医生提供了理论和实践基础。